ASCO 2026版IV期驱动基因阳性非小细胞肺癌治疗指南
PURPOSE: To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer with driver alterations.…
要点
- 指南覆盖驱动基因阳性IV期NSCLC的一线、二线及后续治疗推荐。
- 推荐基于疗效与安全性结局,由多学科专家组采用非正式共识制定。
核心结论
- 本指南整合了既往所有更新,反映了支持该主题的完整证据体系。
- 循证推荐已更新,涵盖驱动基因阳性患者的一线、二线及后续治疗选择。
研究设计与样本
- 专家组由肿瘤内科、肺科、社区肿瘤、研究方法学和倡导专家组成。
- 文献检索包括系统综述、荟萃分析和随机对照试验,关注疗效与安全性结局。
主要发现
- 专家组使用现有证据和非正式共识制定循证指南推荐。
临床怎么用
- 临床可依据本指南更新的一线、二线及后续治疗推荐管理驱动基因阳性IV期NSCLC患者。
- 更多信息可访问www.asco.org/thoracic-cancer-guidelines。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer with driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
引用
- Puri S, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol. 2026. PMID: 41632926. doi:10.1200/JCO-25-02822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。